eXoZymes (NASDAQ:EXOZ) Issues Earnings Results

eXoZymes (NASDAQ:EXOZ) issued its earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, Zacks reports.

eXoZymes Price Performance

Shares of NASDAQ:EXOZ traded up $0.20 during trading on Thursday, reaching $5.96. The stock had a trading volume of 4,541 shares, compared to its average volume of 6,214. eXoZymes has a 52 week low of $4.35 and a 52 week high of $18.40. The business’s 50-day moving average price is $6.67 and its 200 day moving average price is $8.46. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.32 and a quick ratio of 1.32. The stock has a market capitalization of $54.85 million, a PE ratio of -5.22 and a beta of 2.93.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of eXoZymes in a research note on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.